About the webinar

Chimeric antigen receptor (CAR) T cell and natural killer (NK) cell therapy holds tremendous promise as a viable therapeutic option, but it also raises concerns and uncertainty when meeting the desired patient outcome and safety. Hence, robust functional and analytical characterization at every stage of CAR T/NK cell development is needed to quantify the composition, potency, and safety of these therapies. Such detailed characterization done in vitro and in vivo can help monitor and predict their behavior downstream.

This webinar brings together a group of post-doctoral fellows from labs that are developing and using new tools that can reliably characterize CAR T and NK cells. They are keen to share their best practices and technical know-how and provide details on how they can be put to good use. Their short scientific presentations will be followed by a Q&A session to help attendees get more specifics on what is involved.

You will learn about:

• Understanding the differences between CAR T cells and CAR NK cells
• Common challenges associated with the culture and characterization of these cells
• Developments in new assays and technologies for the characterization of CAR T/NK cells
• Impact of structure and distribution of CARs on activity
• Best practices for designing different in vitro and in vivo assays for various measurements
• Differences when working with autologous versus allogenic cells

Download our infographic: A Comparison of CAR-T and CAR-NK Cell Therapies